American Cancer Society: New Prostate Screening Guidelines Advise Routine PSA

• The American Cancer Society now recommends routine prostate cancer screening for middle-aged men.
• Men at average risk should receive a PSA test every two years between ages 50 and 69.
• High-risk men, including Black men and those with a strong family history, should start yearly PSA tests at age 45.
• The updated guidelines incorporate advances in understanding PSA benefits and methods to reduce potential harms.
• Screening is discouraged for men 80 and older or those with a life expectancy under 10 years.

These updated PSA test recommendations men should consider could establish a new standard of care for medical practitioners.

The American Cancer Society (ACS) recently announced a significant alteration to its American Cancer Society prostate screening guidelines, now advocating for routine prostate cancer screening for men in middle age. This updated guidance, issued on Thursday, represents a notable departure from previous recommendations concerning the use of the PSA test recommendations men have received for prostate-specific antigen guidelines. The core of the new advice centers on a straightforward blood test, known as the PSA test.

For men considered to be at an average risk of developing prostate cancer, the ACS now suggests undergoing a PSA test every two years, specifically within the age bracket of 50 to 69. However, for individuals identified as high-risk, which includes Black men and those with a substantial family history of the disease, the recommendations are more intensive. These high-risk groups are advised to receive annual PSA checks, commencing at an earlier age of 45. This ACS prostate cancer screening update emphasizes a more proactive approach to early detection.

This latest ACS prostate cancer screening update signifies a fundamental shift in the prevailing perspective on routine blood tests for prostate-specific antigen. Prior to this revision, specifically since 2010, the cancer society's stance was more consultative, recommending that men at average risk engage in discussions with their physicians to determine the appropriateness of regular PSA testing. The protein, prostate-specific antigen (PSA), is naturally produced by both healthy and cancerous prostate cells. Consequently, an elevated PSA level can indicate the presence of a tumor, but it can also stem from a benign enlarged prostate or even a temporary surge following strenuous physical activity.

Historically, widespread PSA testing faced criticism for contributing to the overtreatment of slow-growing tumors that might never have posed a significant threat. It was also associated with an increase in unnecessary follow-up diagnostic procedures for men who ultimately did not have cancer. The current prostate-specific antigen guidelines have been refined based on advancements in understanding the true benefits of PSA testing and, crucially, how to mitigate its potential drawbacks. These improvements include strategies such as retesting elevated PSA levels to confirm their persistence and integrating MRI scans to more accurately identify individuals who genuinely require a biopsy.

The American Cancer Society prostate screening guidelines also offer specific advice regarding the continuation of screening into later life. For men aged 70 and above, the guidelines suggest a discussion with their healthcare providers to assess the ongoing benefits of routine PSA checks. Conversely, the ACS explicitly discourages screening for men aged 80 and older, as well as for any individual, regardless of age, who is not projected to live for at least another decade due to existing health complications.

Prostate cancer remains one of the most prevalent forms of cancer among men. The ACS projects that in 2026 alone, over 333,000 men across the United States will be diagnosed with prostate cancer, with approximately 36,000 fatalities attributed to the disease. These updated PSA test recommendations men should consider could establish a new standard of care for medical practitioners. Consequently, legal professionals involved in medical malpractice prostate cancer cases will need to be acutely aware of these recommendations, as they may significantly influence assessments of professional negligence related to missed diagnoses or delayed treatment. Furthermore, these revised guidelines could also impact health insurance prostate screening coverage policies, potentially leading to adjustments in what services are routinely covered.

These updated guidelines from the American Cancer Society could establish a new standard of care for medical practitioners regarding prostate cancer screening. Lawyers involved in medical malpractice cases should be aware of these recommendations when assessing claims related to missed diagnoses or delayed treatment, as they may influence the determination of professional negligence.

Source: Original reporting via AP Medical Writer.